MX357528B - Metodos para el tratamiento de trastornos metabolicos usando intercambiadores epimetabolicos, moleculas intracelulares multidimensionales o influencias ambientales. - Google Patents

Metodos para el tratamiento de trastornos metabolicos usando intercambiadores epimetabolicos, moleculas intracelulares multidimensionales o influencias ambientales.

Info

Publication number
MX357528B
MX357528B MX2015007141A MX2015007141A MX357528B MX 357528 B MX357528 B MX 357528B MX 2015007141 A MX2015007141 A MX 2015007141A MX 2015007141 A MX2015007141 A MX 2015007141A MX 357528 B MX357528 B MX 357528B
Authority
MX
Mexico
Prior art keywords
epimetabolic
methods
exchangers
metabolic disorders
treatment
Prior art date
Application number
MX2015007141A
Other languages
English (en)
Spanish (es)
Inventor
Sarangarajan Rangaprasad
Patrick Mccook John
Rajin Narain Niven
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of MX357528B publication Critical patent/MX357528B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
MX2015007141A 2009-05-11 2010-05-11 Metodos para el tratamiento de trastornos metabolicos usando intercambiadores epimetabolicos, moleculas intracelulares multidimensionales o influencias ambientales. MX357528B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17724309P 2009-05-11 2009-05-11
US17724409P 2009-05-11 2009-05-11
US17724109P 2009-05-11 2009-05-11
US17724509P 2009-05-11 2009-05-11
US17724609P 2009-05-11 2009-05-11
PCT/US2010/034447 WO2010132502A2 (en) 2009-05-11 2010-05-11 Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers

Publications (1)

Publication Number Publication Date
MX357528B true MX357528B (es) 2018-07-13

Family

ID=43085533

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2015007141A MX357528B (es) 2009-05-11 2010-05-11 Metodos para el tratamiento de trastornos metabolicos usando intercambiadores epimetabolicos, moleculas intracelulares multidimensionales o influencias ambientales.
MX2011011947A MX2011011947A (es) 2009-05-11 2010-05-11 Metodos para el diagnostico de trastornos metabolicos usando intercambiadores epimetabolicos, moleculas intracelulares multidimensionales, o influyentes ambientales.
MX2011011958A MX2011011958A (es) 2009-05-11 2010-05-11 Metodos para el tratamiento de trastornos metabolicos utilizando cambiadores epimetabólicos, moléculas intracelulares multidimensionales o influenciadores ambientales.
MX2011011949A MX349796B (es) 2009-05-11 2010-05-11 Composiciones farmacéuticas para usarse en el tratamiento de trastornos oncológicos mediante el uso de coenzima q10.
MX2011011942A MX345044B (es) 2009-05-11 2010-05-11 Métodos para el diagnóstico de trastornos oncológicos usando cambiadores epimetabólicos, moléculas intracelulares multidimensionales o influenciadores ambientales.
MX2011011940A MX351083B (es) 2009-05-11 2010-05-11 Métodos para el tratamiento de trastornos oncológicos usando cambiadores epimetabólicos, moléculas intracelulares multidimensionales, o influenciadores ambientales.

Family Applications After (5)

Application Number Title Priority Date Filing Date
MX2011011947A MX2011011947A (es) 2009-05-11 2010-05-11 Metodos para el diagnostico de trastornos metabolicos usando intercambiadores epimetabolicos, moleculas intracelulares multidimensionales, o influyentes ambientales.
MX2011011958A MX2011011958A (es) 2009-05-11 2010-05-11 Metodos para el tratamiento de trastornos metabolicos utilizando cambiadores epimetabólicos, moléculas intracelulares multidimensionales o influenciadores ambientales.
MX2011011949A MX349796B (es) 2009-05-11 2010-05-11 Composiciones farmacéuticas para usarse en el tratamiento de trastornos oncológicos mediante el uso de coenzima q10.
MX2011011942A MX345044B (es) 2009-05-11 2010-05-11 Métodos para el diagnóstico de trastornos oncológicos usando cambiadores epimetabólicos, moléculas intracelulares multidimensionales o influenciadores ambientales.
MX2011011940A MX351083B (es) 2009-05-11 2010-05-11 Métodos para el tratamiento de trastornos oncológicos usando cambiadores epimetabólicos, moléculas intracelulares multidimensionales, o influenciadores ambientales.

Country Status (13)

Country Link
US (15) US9205064B2 (enExample)
EP (5) EP2429511B1 (enExample)
JP (13) JP6169846B2 (enExample)
KR (7) KR20120034649A (enExample)
CN (7) CN102481271A (enExample)
AU (9) AU2010247750B2 (enExample)
BR (5) BRPI1010908A2 (enExample)
CA (5) CA2763336C (enExample)
EA (5) EA201101522A1 (enExample)
IL (5) IL216299A0 (enExample)
MX (6) MX357528B (enExample)
SG (10) SG175994A1 (enExample)
WO (5) WO2010132486A2 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008228764B2 (en) * 2007-03-22 2014-05-08 Berg Llc Topical formulations having enhanced bioavailability
AU2010247750B2 (en) 2009-05-11 2016-09-22 Berg Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
KR102008658B1 (ko) 2010-03-12 2019-08-08 베르그 엘엘씨 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법
CA2810746A1 (en) * 2010-06-30 2012-01-05 Galderma Research & Development Method for preventing or treating skin tumor
SG182016A1 (en) * 2010-12-14 2012-07-30 Univ Singapore Method of detecting resistance to cancer therapy
CA3062500C (en) * 2010-12-20 2022-01-18 Cameron K. Tebbi Methods of detecting leukemia/ lymphoma and induction of the same
US9783785B2 (en) 2010-12-20 2017-10-10 Cameron K. Tebbi Screening methods for detection of susceptibility to leukemia and lymphomas
WO2012097276A2 (en) 2011-01-13 2012-07-19 Expression Pathology, Inc. Bcl-2-like protein 11 srm/mrm assay
US10130684B2 (en) * 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
JP6105491B2 (ja) 2011-03-02 2017-03-29 バーグ エルエルシー 照合性細胞ベースのアッセイ及びその使用
RU2453849C1 (ru) * 2011-03-11 2012-06-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ определения метаболитов углеводного обмена в биологических тканях
KR101933732B1 (ko) * 2011-04-04 2018-12-28 버그 엘엘씨 중추 신경 시스템 종양들의 치료 방법
EP2720689A4 (en) 2011-06-14 2014-11-26 Edison Pharmaceuticals Inc CATECHOL DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATIVE STRESS
JP5932993B2 (ja) 2011-06-17 2016-06-08 バーグ エルエルシー 吸入可能な医薬組成物
CN102453769A (zh) * 2011-12-27 2012-05-16 芮屈生物技术（上海）有限公司 白血病病变前期mRNA水平原位杂交检测试剂盒及检测方法和应用
KR102074530B1 (ko) 2012-03-06 2020-02-06 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 조합 요법에 의한 프로카스파제 ３ 활성화
US10061887B2 (en) 2012-04-02 2018-08-28 Berg Llc Interrogatory cell-based assays and uses thereof
ES2623470T3 (es) * 2012-04-20 2017-07-11 Horizon Therapeutics, Llc HPN-100 para uso en el tratamiento de trastornos de retención de nitrógeno
IN2014DN10734A (enExample) * 2012-06-01 2015-09-04 Berg Llc
JP6059350B2 (ja) * 2012-09-06 2017-01-11 日立化成株式会社 ペプチド特異的免疫の評価のための方法
EP3398594B1 (en) 2012-09-19 2024-07-10 Grespo AB Compositions for improvement of brain function
WO2014059008A1 (en) 2012-10-09 2014-04-17 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
WO2014059009A1 (en) 2012-10-09 2014-04-17 The Procter & Gamble Company Method of identifying synergistic cosmetic combinations
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
EP2967058A4 (en) * 2013-03-15 2017-03-01 The Board of Regents of The University of Texas System Use of inhibitors of mtor to improve vascular functions in apoe4 carriers
EP2976002A1 (en) * 2013-03-19 2016-01-27 The Procter & Gamble Company Method of measuring the metabolic indicators of hair follicles
SG11201508272YA (en) * 2013-04-08 2015-11-27 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
WO2014181968A1 (ko) * 2013-05-09 2014-11-13 가톨릭대학교 산학협력단 메트포민과 코엔자임 q10을 유효성분으로 함유하는 면역 질환의 예방 또는 치료용 조성물
US20160193231A1 (en) * 2013-06-26 2016-07-07 Rett Syndrome Research Trust Rett syndrome and treatments therefore
HUE050060T2 (hu) 2013-09-04 2020-11-30 Berg Llc Eljárások rák kezelésére koenzim Q10 folyamatos infúziójával
CN103585619A (zh) * 2013-10-31 2014-02-19 浙江大学 Dj-1蛋白在制备骨肉瘤诊断和治疗产品中的应用
ES2875899T3 (es) 2013-11-22 2021-11-11 Sabre Therapeutics Llc Compuestos inhibidores de autotaxina
WO2015084862A1 (en) * 2013-12-02 2015-06-11 Fu-Shin Yu Compositions and methods to diagnose diabetes and/or to treat negative effects of diabetes
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US20160341739A1 (en) * 2014-01-15 2016-11-24 The Regents Of The University Of California Metabolic screening for gestational diabetes
AU2015243936B2 (en) * 2014-04-07 2021-08-05 Memorial Sloan Kettering Cancer Center Modulating cell proliferation and pluripotency
WO2015157345A2 (en) * 2014-04-07 2015-10-15 Wake Forest University Health Sciences Bioenergetic profiling of circulating blood cells and systems, devices, and methods relating thereto
JP6487031B2 (ja) * 2014-04-17 2019-03-20 イミューノメット セラピューティクス インコーポレイテッド グアニジン化合物、及びその用途
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
WO2016031816A1 (ja) * 2014-08-26 2016-03-03 学校法人慶應義塾 抗がん剤の感受性の判定マーカー
CN114203296B (zh) 2014-09-11 2025-10-17 布普格生物制药公司 基于患者数据的用于健康护理诊断和治疗的贝叶斯因果关系网络模型
JP6873919B2 (ja) 2015-05-27 2021-05-19 セイバー セラピューティクス エルエルシー オートタキシン阻害剤とその使用
WO2017040520A1 (en) 2015-08-31 2017-03-09 Hitachi Chemical Co., Ltd. Molecular methods for assessing urothelial disease
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
WO2017100789A1 (en) * 2015-12-11 2017-06-15 Expression Pathology, Inc. Srm/mrm assays
WO2018096076A1 (en) * 2016-11-25 2018-05-31 Koninklijke Philips N.V. Method to distinguish tumor suppressive foxo activity from oxidative stress
US20210130291A1 (en) 2016-12-22 2021-05-06 The National Institute for Biotechnology in the Negev Ltd. Methods for treating diabetes using vdac1 inhibitors
CN110191946A (zh) 2016-12-23 2019-08-30 学校法人庆应义塾 诱导cd8+t细胞的组合物及方法
MA52274A (fr) 2017-05-17 2021-02-24 Berg Llc Utilisation de formulations de coenzyme q10 dans le traitement et la prévention de l'épidermolyse bulleuse
CN109111522B (zh) * 2017-06-22 2022-02-01 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
JP7209951B2 (ja) * 2017-10-30 2023-01-23 日本メナード化粧品株式会社 白髪予防及び改善剤
AU2018368453B2 (en) 2017-11-17 2024-05-30 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
AU2019217041B2 (en) * 2018-02-09 2022-09-15 Keio University Compositions and methods for the induction of CD8+ T-cells
CN112955139B (zh) 2018-09-25 2025-04-18 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
WO2020072774A1 (en) 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
IL284700B2 (en) 2019-01-23 2025-10-01 Regeneron Pharma Treating eye conditions with angiopoietin-like 7 inhibitors
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
GB201911095D0 (en) * 2019-08-02 2019-09-18 Randox Laboratories Ltd Biological status classification
WO2021102356A1 (en) 2019-11-20 2021-05-27 Berg Llc Combination therapy of a coenzyme q10 compound and radiation therapy for treatment of glioma
CN112924681B (zh) * 2019-12-05 2023-01-17 张曼 尿液krt10蛋白及其多肽片段在正常妊娠中的应用
KR102383788B1 (ko) * 2020-06-12 2022-04-05 이화여자대학교 산학협력단 신체적 스트레스 상태를 평가하는 방법
CA3188646A1 (en) * 2020-07-02 2022-01-06 Ponce De Leon Health Designated Activity Company Compositions and methods for treating crp-mediated diseases
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
US20230398110A1 (en) * 2020-08-21 2023-12-14 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US12018259B2 (en) 2020-12-23 2024-06-25 Regeneron Pharmaceuticals, Inc. Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors
KR20230148819A (ko) 2021-02-26 2023-10-25 리제너론 파마슈티칼스 인코포레이티드 글루코코르티코이드 및 안지오포이에틴-유사 7 (angptl7) 억제제를 이용한 염증의 치료
JP7650205B2 (ja) * 2021-07-20 2025-03-24 株式会社カネカ 血中の補酵素ｑを定量する方法
CN114306608B (zh) * 2022-01-04 2024-01-16 上海科技大学 一类适应低氧或缺氧微环境的肿瘤的治疗靶点及其应用
CN115440303B (zh) * 2022-11-03 2023-02-10 杭州联川生物技术股份有限公司 一种单细胞转录组低质量细胞过滤方法、介质和设备
CN117347643B (zh) * 2023-12-05 2024-02-06 成都泰莱生物科技有限公司 用于判断肺部结节良恶性的代谢标志物组合及其筛选方法和应用
WO2025155991A2 (en) 2024-01-19 2025-07-24 Bpgbio, Inc. Predictive biomarkers for response to coenzyme q10 treatment in pancreatic cancer

Family Cites Families (400)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525350A (en) * 1975-02-20 1985-06-25 The New England Institute, Inc. Methods of stimulating host defense system with coenzymes Q4 to Q.sub.1
JPS5775916A (en) 1980-10-29 1982-05-12 Nippon Chemiphar Co Ltd Coenzyme q pharmaceutical and its preparation
JPS58113127A (ja) 1981-12-28 1983-07-05 Ajinomoto Co Inc ユビデカレノン含有水性液
IT1157269B (it) * 1982-03-19 1987-02-11 Seuref Ag Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica
JPS58201711A (ja) 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US4833128A (en) 1984-12-28 1989-05-23 Neil Solomon Dietary supplement
US4824669A (en) 1985-04-11 1989-04-25 Board Of Regents, The University Of Texas System Formulations of coenzyme Q10 for intravenous use
US4895727A (en) 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
JPS62123113A (ja) 1985-11-22 1987-06-04 Green Cross Corp:The ユビデカレノン含有脂肪乳剤
US4843071A (en) 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
JP2600726B2 (ja) 1987-11-30 1997-04-16 大正製薬株式会社 微粒子脂肪乳剤
GB8811410D0 (en) 1988-05-13 1988-06-15 Unilever Plc Treatment of skin disorders
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
JP2828655B2 (ja) 1989-04-14 1998-11-25 エーザイ株式会社 脂溶性薬物含有水性液
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5962243A (en) 1990-04-18 1999-10-05 Board Of Regents, The University Of Texas System Methods for the identification of farnesyltransferase inhibitors
JP3008131B2 (ja) 1990-11-14 2000-02-14 ロレアル グリセリンから誘導される非イオン両親媒性化合物、その調製方法、相応する中間体化合物及び前記化合物を含有する組成物
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
US5378461A (en) * 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
US6461593B1 (en) 1992-02-19 2002-10-08 Biomedical And Clinical Research Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
AU676470B2 (en) 1992-02-24 1997-03-13 East Carolina University Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof
US6093706A (en) 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
FR2697841B1 (fr) 1992-11-12 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
JP3526575B2 (ja) 1993-03-08 2004-05-17 エーザイ株式会社 ホスホン酸誘導体
ATE166573T1 (de) 1993-03-24 1998-06-15 Ciba Geigy Ag Verfahren zur herstellung einer liposomendispersion im hochdruckbereich
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
DE4410238A1 (de) 1994-03-25 1995-09-28 Beiersdorf Ag Hautpflegemittel
US20020049422A1 (en) 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
EP0796108A2 (en) 1994-12-06 1997-09-24 Ryan Pharmaceuticals, Inc. Water soluble ubiquinone compositions, prodrugs, and methods relating thereto
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US6005086A (en) 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
DE19537027A1 (de) 1995-10-05 1997-04-10 Beiersdorf Ag Hautpflegemittel für alte Haut
EP0856026A1 (en) 1995-10-19 1998-08-05 Receptagen Corporation Discrete-length polyethylene glycols
US5944012A (en) 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
DE19615577A1 (de) * 1996-04-19 1997-10-23 Beiersdorf Ag Verwendung von Salicin als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
US5891465A (en) 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
GB9625895D0 (en) 1996-12-13 1997-01-29 Riley Patrick A Novel compound useful as therapeutic agents and assay reagents
US20040228910A1 (en) 1997-02-11 2004-11-18 Mse Pharmazeutika Gmbh Transdermal, oral and intravenous formulations of 2, 3-dimethoxy-5-methyl-6-decaprenyl-1, 4-benzoquinone
DE59800863D1 (de) 1997-02-11 2001-07-19 Mse Pharmazeutika Gmbh Transdermale, orale und intravenöse zubereitungen von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon
US6228891B1 (en) 1997-02-12 2001-05-08 Mse Pharmazeutika Gmbh Use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6372234B1 (en) 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6599513B2 (en) 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6726924B2 (en) * 1997-09-04 2004-04-27 Biozone Laboratories, Inc. Oral liposomal delivery system
EP1027045A4 (en) 1997-10-31 2004-12-08 Arch Dev Corp METHODS AND COMPILATIONS FOR REGULATING S-ALPHA REDUCTASE ACTIVITY
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6372880B1 (en) 1997-12-25 2002-04-16 Mitsui Chemicals, Inc. Copolymer and process for preparing the same
US6048846A (en) 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
AU759467B2 (en) 1998-04-02 2003-04-17 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
CA2736981A1 (en) 1998-04-14 1999-10-21 Kyowa Hakko Bio Co., Ltd. Process for producing isoprenoid compounds by microorganisms
US6503523B2 (en) * 1998-05-07 2003-01-07 Gs Development A.B. Skin care agents containing combinations of active agents consisting of vitamin a derivatives and UBI- or plastoquinones
CN1160059C (zh) 1998-06-19 2004-08-04 斯凯伊药品加拿大公司 生产水不溶性化合物的亚微粒子的方法
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
DE19828081C2 (de) 1998-06-24 2000-08-10 Cognis Deutschland Gmbh W/O-Emulsionsgrundlagen
JP2002520511A (ja) 1998-07-16 2002-07-09 コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｉｔエマルジョンの使用
EP1098641B1 (en) 1998-07-27 2016-04-27 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
CA2339473A1 (en) 1998-08-04 2000-02-17 John V. Kosbab Nutrient and therapeutic compositions for the treatment of cancer
WO2000016772A1 (en) * 1998-09-23 2000-03-30 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6048886A (en) * 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
IT1304406B1 (it) * 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US20040034107A1 (en) 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
US20050019268A1 (en) 1999-02-11 2005-01-27 Mse Pharmazeutika Gmbh Spray containing ubiquinone Qn
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
US6140067A (en) * 1999-04-30 2000-10-31 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
US6803193B1 (en) 1999-06-23 2004-10-12 The Penn State Research Foundation Methods to identify modulators of the mevalonate pathway in sterol synthesis
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
EP1064913B1 (de) * 1999-07-02 2005-09-14 Cognis IP Management GmbH Mikrokapseln - III
US6630160B1 (en) 1999-09-07 2003-10-07 Genetic Services Management, Inc. Process to modulate disease risk with doses of a nutraceutical
US20030104080A1 (en) 1999-09-07 2003-06-05 Singh Parashu Ram Topical urea composition
US7005274B1 (en) 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
CA2385139A1 (en) 1999-10-14 2001-04-19 The Nisshin Oil Mills, Ltd. Skin-beautifying agent, anti-aging agent for the skin, whitening agent and external agent for the skin
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
US20020049176A1 (en) * 1999-11-10 2002-04-25 Anderson Christen M. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7083780B2 (en) 1999-12-11 2006-08-01 Cognis Deutschland Gmbh & Co. Kg Cosmetic composition containing hydroxyethers
EP1239826A2 (de) 1999-12-20 2002-09-18 Cognis France S.A. Kosmetische und/oder pharmazeutische zubereitungen
AUPQ515000A0 (en) 2000-01-19 2000-02-10 Grigg, Geoffrey Walter Treatment of uv induced immunosuppression
CN1416341B (zh) 2000-02-04 2010-05-05 武田药品工业株式会社 稳定的乳液组合物
NZ509803A (en) 2000-02-09 2001-08-31 Paul A Treatment of fibromyalgia with ubiquinone 10 and succinic acid
FR2804864B1 (fr) 2000-02-11 2003-04-04 Serobiologiques Lab Sa Extraits de residus issus de la fabrication du vin et leur utilisation en cosmetique ou pharmacologie
US20020044913A1 (en) * 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
DE10007322A1 (de) * 2000-02-17 2001-08-23 Cognis Deutschland Gmbh Perlglanzmittel
EP1127567B1 (de) 2000-02-17 2010-09-01 Basf Se Wässrige Dispersion wasserunlöslicher organischer UV-Filtersubstanzen
FR2805464B1 (fr) 2000-02-25 2003-02-14 Serobiologiques Lab Sa Preparations cosmetiques contenant des extraits de la plante mourera fluviatilis
DE10009996B4 (de) 2000-03-02 2005-10-13 Cognis Ip Management Gmbh Feststoffgranulate mit monodisperser Korngrößenverteilung, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
US6866864B2 (en) 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
JP2004500404A (ja) 2000-03-27 2004-01-08 カール　−　ツァイス　−　シュティフツング 生物活性ガラスを含む新規化粧品、ボディケア、洗浄剤および栄養サプリメント組成物および製造方法およびその使用
US6447760B2 (en) 2000-05-08 2002-09-10 Playtex Products, Inc. Sunless tanning compositions
AU780910B2 (en) 2000-05-09 2005-04-21 Kaneka Corporation Dermal compositions containing coenzyme Q as the active ingredient
US6468552B1 (en) 2000-06-02 2002-10-22 Neutrogena Corporation Stabilized compositions containing oxygen-labile active agents
SE0002189D0 (sv) 2000-06-09 2000-06-09 Metcon Medicin Ab New method and assay
DE10031703A1 (de) * 2000-06-29 2002-01-10 Beiersdorf Ag Verwendung von Calcium freisetzenden oder bindenden Substanzen zur gezielten Schächung oder Stärkung der Barrierefunktion der Haut
EP1170015A1 (de) 2000-07-06 2002-01-09 Laboratoires Serobiologiques(Societe Anonyme) Verwendung von Extrakten des Pilzes Grifola frondosa
DE10033022A1 (de) * 2000-07-07 2002-01-17 Cognis Deutschland Gmbh Aerosole
US20030012825A1 (en) 2000-07-10 2003-01-16 Charles Kapper Metallized molecule therapies
US6465517B1 (en) 2000-07-11 2002-10-15 N.V. Nutricia Composition for the treatment of migraine
DE10034619A1 (de) 2000-07-17 2002-01-31 Cognis Deutschland Gmbh Aniontensidfreie niedrigviskose Trübungsmittel
DE10036655A1 (de) 2000-07-26 2002-02-07 Basf Ag Kosmetische oder dermatologische Zubereitungen zur Vermeidung von Hautschädigungen durch Peroxide
DE10036799A1 (de) 2000-07-28 2002-02-07 Beiersdorf Ag Neues Mittel zur Behandlung der Haare und der Kopfhaut
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20020045230A1 (en) 2000-08-14 2002-04-18 Rosen Craig A. Nucleic acids, proteins, and antibodies
US6441050B1 (en) 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
FR2813195B1 (fr) 2000-08-29 2003-04-04 Serobiologiques Lab Sa Utilisation d'extraits de la plante cassia alata dans des produits de soin
DE10048260A1 (de) 2000-09-29 2002-04-11 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Aminoguanidin und/oder dessen Derivaten und Strukturanaloga zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE10053328A1 (de) * 2000-10-27 2002-05-08 Cognis Deutschland Gmbh Kosmetische Zubereitungen
US6689385B2 (en) 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
US6403116B1 (en) 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
IT1317938B1 (it) 2000-11-17 2003-07-15 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di alterazioni delmetabolismo lipidico, delle forme allergiche e per attivare le difese
US20070003536A1 (en) * 2000-11-21 2007-01-04 Zimmerman Amy C Topical skin compositions, their preparation, and their use
AUPR177300A0 (en) 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
JP2004515508A (ja) 2000-12-16 2004-05-27 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 化合物の健康促進組成物
DE10064818A1 (de) 2000-12-22 2002-06-27 Basf Ag Verwendung von Chroman-Derivaten in kosmetischen oder dermatologischen Zubreitungen
US6806069B2 (en) 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
FR2819414A1 (fr) 2001-01-15 2002-07-19 Cognis France Sa Preparations cosmetiques et/ou pharmaceutiques comprenant des extraits de plantes dites a resurrection
AU2002226650A1 (en) 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
EP1353667A1 (en) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
NL1017205C2 (nl) 2001-01-26 2002-07-29 Adriaan Emanuel Hendricus Wiel Medicinale en cosmetische toepassing van hop en co-enzym Q10.
ITRM20010044A1 (it) * 2001-01-29 2002-07-29 Sigma Tau Healthscience Spa Integratore alimentare ad effetto dimagrante.
JP2005503999A (ja) 2001-01-31 2005-02-10 アイデック ファーマスーティカルズ コーポレイション 腫瘍性疾患の治療のためのｃｄ２３拮抗剤の使用
ITMI20010204A1 (it) 2001-02-02 2002-08-02 Hunza Di Marazzita Maria Carme Specialita' terapeutiche dotate di attivita' antiossidante ed in grado di controllare l'eccesso del peso corporeo
FR2821624B1 (fr) 2001-03-01 2004-01-02 Sod Conseils Rech Applic Nouveau polynucleotide utilisable pour moduler la proliferation des cellules cancereuses
IL157367A0 (en) 2001-03-09 2004-02-19 Nestle Sa Composition improving age-related physiological deficits and increasing longevity
DE10113053A1 (de) 2001-03-15 2002-09-19 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen mit anorganischen Gelbildnern und organischen Hydrololloiden
DE10113046A1 (de) 2001-03-15 2002-09-26 Beiersdorf Ag Selbstschäumende schaumförmige Zubereitungen mit organischen Hydrokolliden und partikulären hydrophobisierten und/oder ölabsorbierenden Festkörpersubstanzen
DE10113050A1 (de) 2001-03-15 2002-09-19 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen organischen Hydrokolloiden
EP1243252B1 (fr) 2001-03-23 2006-05-24 L'oreal Composition pour le peau, contenant des fibres et des ubiquinones
US20030031688A1 (en) * 2001-04-02 2003-02-13 Dipak Ghosh Cosmetic composition with improved skin moisturizing properties
US6727234B2 (en) 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
US6469061B1 (en) 2001-04-04 2002-10-22 Ramot University Authority For Applied Research And Industrial Development Limited Jasmonate pharmaceutical composition for treatment of cancer
DE10118269A1 (de) * 2001-04-12 2002-10-17 Cognis Deutschland Gmbh Kosmetische Zubereitungen
US6686485B2 (en) * 2001-04-19 2004-02-03 Daniel David West Synthesis of coenzyme Q10, ubiquinone
WO2002085297A2 (en) 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
US20040049022A1 (en) 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
WO2002085308A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US6582723B2 (en) 2001-05-03 2003-06-24 Wayne F. Gorsek Cancer immune composition for prevention and treatment of individuals
JP3742602B2 (ja) 2001-05-09 2006-02-08 株式会社カネカ 還元型補酵素ｑの安定な溶液
US7754205B2 (en) 2001-05-10 2010-07-13 Kaneka Corporation Composition for transmucosal administration containing conenzyme Q as the active ingredient
JP4603192B2 (ja) 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
GB0111279D0 (en) 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
DE10123771B4 (de) 2001-05-16 2019-01-10 Beiersdorf Ag Verwendung von Elektrolyten zur Stärkung der Barrierefunktion der Haut
EP1260212A1 (de) 2001-05-21 2002-11-27 Cognis France S.A. Kosmetische Mittel
US20050118151A1 (en) * 2001-05-29 2005-06-02 Syddansk Universitet Proteins in diabetes proteome anlysis
SK14502003A3 (en) 2001-05-30 2004-10-05 Laxdale Ltd Coenzyme Q and eicosapentaenoic acid
US20030138792A1 (en) * 2001-05-31 2003-07-24 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
EP1262167A1 (de) 2001-06-01 2002-12-04 Cognis France S.A. Kosmetische Zubereitungen enthaltend ein Extrakt von keimenden Pflanzen
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
US6696060B2 (en) 2001-06-14 2004-02-24 Clearant, Inc. Methods for sterilizing preparations of monoclonal immunoglobulins
US6506915B1 (en) * 2001-06-14 2003-01-14 Daniel David West Synthesis of coenzyme Q10 ubiquinone
FR2826017B1 (fr) 2001-06-15 2004-06-11 Cognis France Sa Melanges de tensioactifs
SE0102380D0 (sv) 2001-07-02 2001-07-02 Macronova Ab Kräm för behandling av åldersförändringar i huden hos människa
DE10133198A1 (de) 2001-07-07 2003-01-23 Beiersdorf Ag Kreatin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
JP2003020495A (ja) 2001-07-10 2003-01-24 Cognis Japan Ltd 油脂組成物
EP2351765A3 (en) 2001-07-10 2012-02-22 Lakewood-Amedex, Inc Oligonucleotide-containing pharmacological compositions and their use
CH695085A5 (de) 2001-07-13 2005-12-15 Mibelle Ag Cosmetics Formulierungen zur Pflege der Haut nach Laserbehandlungen und/oder chemischen Peelings und Verwendung der Formulierungen.
TWI235146B (en) * 2001-07-16 2005-07-01 Kaneka Corp Method of stabilizing reduced coenzyme q10 and method of acidic crystallization
WO2003007889A2 (en) 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
FR2827603B1 (fr) 2001-07-18 2003-10-17 Oreal Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques
WO2003009704A2 (en) 2001-07-27 2003-02-06 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
EP1281392A1 (de) 2001-08-02 2003-02-05 Cognis France S.A. Kosmetische und/oder pharmaceutische Zubereitungen enthaltend Pflanzenextrakte
DE10139580A1 (de) * 2001-08-10 2003-02-20 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen mit einem Gehalt an Sterinen und/oder C12-C40-Fettsäuren
US6503506B1 (en) 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
DE10143962A1 (de) 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
DE10143963A1 (de) 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von W/O-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
DE10143964A1 (de) 2001-09-07 2003-03-27 Basf Ag Emulgatorarme oder emulgatorfreie Systeme vom Typ Öl-in-Wasser mit einem Gehalt an Stabilisatoren und einem aminosubstituierten Hydroxybenzophenon
EP1432400A1 (en) 2001-09-18 2004-06-30 Ciba SC Holding AG Use of guaiol for treating the skin
DE10150725A1 (de) * 2001-10-13 2003-04-17 Cognis Deutschland Gmbh Aniontensidfreie niedrigviskose Trübungsmittel
US7247714B2 (en) 2001-10-16 2007-07-24 Atherogenics, Inc. Protection against oxidative stress and inflammation by a cytoprotective response element
US7560123B2 (en) 2004-08-12 2009-07-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
ES2261760T3 (es) 2001-10-26 2006-11-16 Cognis Ip Management Gmbh Solucion impregnante para toallitas cosmeticas.
US6723527B2 (en) 2001-10-26 2004-04-20 Board Of Regents, The University Of Texas System Methods for determining toxicity reversing agents
MXPA04004219A (es) 2001-11-03 2004-09-10 Astrazeneca Ab Derivados de quinazolina como agentes antitumorales.
US20030118536A1 (en) 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
US6753325B2 (en) 2001-11-06 2004-06-22 The Quigley Corporation Composition and method for prevention, reduction and treatment of radiation dermatitis
US20030105027A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US20030105031A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders
US7435725B2 (en) 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
KR20040068545A (ko) * 2001-11-09 2004-07-31 메드스타 리서치 인스티튜트 심혈관 위험을 추정하는 생리학적 마커의 사용 방법
DE10155769A1 (de) 2001-11-14 2003-05-22 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Emulsionen
DE10160682A1 (de) 2001-12-11 2003-06-18 Cognis Deutschland Gmbh Emollients und kosmetische Zusammensetzungen
US6652891B2 (en) 2001-12-12 2003-11-25 Herbasway Laboratories, Llc Co-enzyme Q10 dietary supplement
DE10162351A1 (de) * 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Emulsionen
DE10162026A1 (de) 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Hochkonzentriert fließfähige Perlglanzkonzentrate
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
TWI349039B (en) 2001-12-27 2011-09-21 Kaneka Corp Processes for producing coenzyme q10
US20030129253A1 (en) 2002-01-03 2003-07-10 Milley Christopher J. Stable aqueous suspension
TW200302056A (en) 2002-01-18 2003-08-01 Kaneka Corp Method for stabilizing reduced coenzyme Q10 and composition therefor
WO2003059312A2 (de) 2002-01-18 2003-07-24 Basf Aktiengesellschaft Kosmetische oder dermatologische zubereitungen, enthaltend bor-organische verbindungen zur vermeidung von hautschädigungen durch peroxide
AU2003205656B2 (en) 2002-01-31 2007-09-06 Ciba Specialty Chemicals Holding Inc. Micropigment mixtures
DE60307234T2 (de) 2002-02-12 2007-07-05 Dsm Ip Assets B.V. Sonnenschutzzusammensetzungen sowie dihydropyridine und dihydropyrane
AU2003205738A1 (en) 2002-02-14 2003-09-04 Dsm Ip Assets B.V. Water-dispersible coenzyme q10 dry powders
EP1340486A1 (de) 2002-03-01 2003-09-03 Cognis France S.A. Verwendung von Zuckerestern
US20030167556A1 (en) 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
DE10254315A1 (de) 2002-03-15 2003-10-02 Cognis Deutschland Gmbh Emollients und kosmetische Zubereitungen
TW200304372A (en) * 2002-03-20 2003-10-01 Kanegafuchi Chemical Ind Compositions for diabetes
CN1856708A (zh) 2002-03-20 2006-11-01 普赖德普罗特奥米克斯公司 人糖尿病介导蛋白
DE10212528A1 (de) * 2002-03-21 2003-10-02 Cognis Deutschland Gmbh Ölphasen für kosmetische Mittel
US7811594B2 (en) * 2002-03-28 2010-10-12 Beiersdorf Ag Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions
DE10213957A1 (de) * 2002-03-28 2003-10-09 Beiersdorf Ag Vernetzte kosmetische oder pharmazeutische phospholipidhaltige Gele und Emulsionen auf der Basis von ethylenoxidhaltigen oder propylenoxidhaltigen Emulgatoren
US20040101874A1 (en) * 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
DE10217474A1 (de) 2002-04-19 2003-11-06 Cognis Deutschland Gmbh Sonnenschutzemulsion mit Schaumspender
US20060193905A1 (en) 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
WO2003099264A1 (en) 2002-05-23 2003-12-04 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
DE10223486A1 (de) * 2002-05-27 2003-12-11 Beiersdorf Ag Kosmetische und/oder dermatologische Zubereitung mit 2,3-Dibenzylbutyrolactonen
ATE334654T1 (de) 2002-06-03 2006-08-15 Ciba Sc Holding Ag Vor uv-strahlen schützende zusammensetzungen
US7182950B2 (en) 2002-06-12 2007-02-27 Nutralease Ltd. Nano-sized self-assembled liquid dilutable vehicles
DE10226018A1 (de) * 2002-06-12 2003-12-24 Cognis Deutschland Gmbh Zubereitungen mit konjugiertem Linolalkohol
US7147841B2 (en) 2002-06-17 2006-12-12 Ciba Specialty Chemicals Corporation Formulation of UV absorbers by incorporation in solid lipid nanoparticles
AU2003246592A1 (en) 2002-06-26 2004-01-19 Europroteome Ag Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
US7060733B2 (en) 2002-08-15 2006-06-13 The Regents Of The University Of California Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species
AU2003279035B2 (en) 2002-09-25 2009-03-12 University Of Rochester Caspase inhibitors as anticancer agents
US6953786B2 (en) * 2002-10-01 2005-10-11 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
FR2845602B1 (fr) * 2002-10-11 2005-07-08 Servier Lab Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
EP1421929A3 (de) 2002-11-21 2004-11-24 Cognis Deutschland GmbH & Co. KG Emollients und kosmetische Zubereitungen
DE10256881A1 (de) 2002-12-05 2004-06-24 Beiersdorf Ag Neue topische Verwendung von Bis-Arylimidazo[1,2-a]thiolanderivaten
US20040110848A1 (en) 2002-12-10 2004-06-10 Peffley Dennis M Method and kit for treating cancer
EP1583829A4 (en) 2002-12-16 2007-08-01 Garvan Inst Med Res METHOD FOR TREATING FEEDING TROUBLE-SHOOTING OR GLUCOSE TAKING-UP AND FOR METABOLISM CHANGING AND IDENTIFICATION OF THERAPEUTIC REAGENTS THEREFOR
CA2511501A1 (en) 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US8557512B2 (en) 2003-01-02 2013-10-15 HMI Medical Innovations, LLC Method of screening activators and/or inhibitors of insulin receptor substrate 2
US20090036516A1 (en) 2003-01-13 2009-02-05 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
KR101064902B1 (ko) 2003-01-20 2011-09-16 시바 홀딩 인코포레이티드 Ｕｖ 흡수제로서 트리아진 유도체
JP2006514661A (ja) 2003-02-03 2006-05-11 デーエスエム アイピー アセッツ ベー． ヴェー． 新規な安定化されたケイ皮酸エステルサンスクリーン組成物
US7258876B2 (en) 2003-02-05 2007-08-21 Craig Bozzacco Topical composition for treating infectious conditions of skin and mucosa
CN1208052C (zh) 2003-03-20 2005-06-29 上海家化联合股份有限公司 一种辅酶q10前体脂质体及其制备方法
BRPI0408994B1 (pt) 2003-03-24 2015-07-14 Ciba Specialty Chemicals Holding Inc. Uso não terapêutico de derivados de triazina simétrica, sua preparação cosmética, bem como seu processo de preparação
WO2004096137A2 (en) 2003-04-08 2004-11-11 Barrie Tan Annatto extract compositions, including geranyl geraniols and methods of use
US20050037102A1 (en) 2003-07-18 2005-02-17 Barrie Tan Annatto extract compositions including tocotrienols and tocopherols and methods of use
JP2004321171A (ja) * 2003-04-11 2004-11-18 Fancl Corp 飲食品
EP1473043A1 (en) 2003-04-29 2004-11-03 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
JP2004345988A (ja) 2003-05-21 2004-12-09 Eisai Co Ltd リボフラビン系化合物を含む医薬組成物
US7438903B2 (en) 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20040253323A1 (en) 2003-06-11 2004-12-16 Giles Brian C. Ionic cancer therapy and methods for using same in the treatment of tumors and metastasis
JP2007521279A (ja) 2003-06-25 2007-08-02 アーウィン、チャールス コエンザイムｑ１０の分配を増加するための化合物及び方法
US20050026848A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
US20070248693A1 (en) 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
US8802161B2 (en) 2003-08-02 2014-08-12 Florida Agricultural And Mechanical University Herbal composition and method of use for the treatment of cancer
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US20050036976A1 (en) * 2003-08-12 2005-02-17 Joel Rubin Topical skin care composition
WO2005020940A1 (de) * 2003-08-27 2005-03-10 Beiersdorf Ag Kapsel deren kapselhülle bei topischer anwendung nicht mehr gesondert warhnembar ist
WO2005032278A1 (en) 2003-09-29 2005-04-14 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
JP2007507432A (ja) 2003-10-02 2007-03-29 セムバイオシス ジェネティクス インコーポレイテッド 活性成分を含む油体を調製するための方法
DE10347218A1 (de) 2003-10-10 2005-05-12 Cognis Deutschland Gmbh Sonnenschutzmittel
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
DE10347940A1 (de) 2003-10-15 2005-05-19 Cognis Deutschland Gmbh & Co. Kg Selbstemulgierende Zubereitungen
JP4732898B2 (ja) 2003-10-31 2011-07-27 株式会社カネカ 還元型補酵素ｑ含有組成物
ES2334797T3 (es) 2003-11-05 2010-03-16 Dsm Ip Assets B.V. Composicion protectora de la luz con una cantidad total reducida de filtro uv que contiene un filtro uv a base de polisiloxano.
US20050100537A1 (en) * 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
WO2005048925A2 (en) 2003-11-14 2005-06-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
DE10354052A1 (de) 2003-11-17 2005-06-16 Beiersdorf Ag Kosmetikum mit empfindlichen Inhaltsstoffen
US20050118235A1 (en) 2003-12-02 2005-06-02 Shiguang Yu Dietary non-essential amino acid tyrosine regulates the body weight of animals through regulating the animal appetite or food intake
RU2355378C2 (ru) 2003-12-18 2009-05-20 Нестек С.А. Содержащая флаваноны композиция для улучшения здоровья кожи, волос и шерсти животных
JP4742526B2 (ja) * 2003-12-26 2011-08-10 シンフォニアテクノロジー株式会社 Ｉｃチップ実装体の製造方法及び製造装置
KR101395370B1 (ko) 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
US20050226947A1 (en) * 2004-02-04 2005-10-13 Dale Kern Agents for sequestering serum aging factors and uses therefore
US20070149618A1 (en) 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
AU2005213895A1 (en) * 2004-02-19 2005-09-01 Chemaphor Inc. Topical formulations for the treatment of skin conditions
MXPA06009529A (es) 2004-02-23 2007-04-10 Texas A & M Univ Sys Composiciones antioxidantes y metodos para el uso de las mismas.
US7780873B2 (en) 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
US20050202521A1 (en) 2004-03-10 2005-09-15 Albert Crum Methods of assessing the need for and the effectiveness of therapy with antioxidants
DE102004014615A1 (de) 2004-03-23 2005-10-13 Beiersdorf Ag Taurinhaltige Zubereitungen zur Verbesserung der Hautbarriere
BRPI0509712A (pt) * 2004-04-06 2007-09-18 Basf Ag método de proteger a pele humana ou o cabelo humano da radiação ultravioleta, formulação para cuidados pessoais contendo protetor solar para proteger a pele humana ou cabelo humano da radiação ultravioleta, e, partìcula tratada na superfìcie
US20050226858A1 (en) 2004-04-09 2005-10-13 Kaneka Corporation Compositions containing reduced coenzyme Q10 and carotenoid
US7351739B2 (en) 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US7723569B2 (en) 2004-04-30 2010-05-25 National Institute Of Agrobiological Sciences Method for producing ubiquinone-10 in plant
IL161899A0 (en) 2004-05-10 2005-11-20 Hoffman Arnold Kit for treatment of cancer
JP2005323573A (ja) 2004-05-17 2005-11-24 Sumitomo Pharmaceut Co Ltd 遺伝子発現データ解析方法および、疾患マーカー遺伝子の選抜法とその利用
RU2375053C2 (ru) 2004-05-18 2009-12-10 Кемийски Инштитут Новая водорастворимая форма коэнзима q10 в форме комплекса включения с бета-циклодекстрином, способ ее получения и ее применение
AU2005247092B2 (en) 2004-05-24 2010-01-07 Basf Aktiengesellschaft Keratin-binding polypeptides
KR20050112942A (ko) 2004-05-28 2005-12-01 주식회사 뉴트렉스테크놀러지 비만 억제용 조성물
US20050288333A1 (en) 2004-06-08 2005-12-29 Kem William R Controlling angiogenesis with anabaseine analogs
CN101005828B (zh) 2004-06-17 2012-01-11 维尔恩公司 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物
US9987217B2 (en) 2004-06-18 2018-06-05 Symrise Ag Blackberry extract
KR20070032795A (ko) * 2004-06-21 2007-03-22 허치슨 메디파르마 엔터프라이즈 리미티드 항암 화학요법
WO2006000350A2 (en) * 2004-06-28 2006-01-05 Dsm Ip Assets B.V. Cosmetic compositions containing protein hydrolysates
RU2007105138A (ru) 2004-07-13 2008-08-20 Оридис Биомед Форшунгс-Унд Энтвиклунгс Гмбх (At) Применение митохондриально направленного антиоксиданта при лечении болезней печени и эпителиальных раковых опухолей
US20060069068A1 (en) 2004-07-15 2006-03-30 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by pathological calcification
CN101065132A (zh) 2004-07-28 2007-10-31 雷蒙德·M·普莱瓦 鸸鹋油和水果组合物
JP2006070016A (ja) 2004-08-02 2006-03-16 Kaneka Corp 還元型補酵素ｑを含有する美白用組成物
WO2006017494A2 (en) * 2004-08-02 2006-02-16 Elizabeth Mazzio Inhibition of anaerobic glucose metabolism
CA2578529A1 (en) 2004-08-18 2006-02-23 Ace Aps Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
WO2006023342A2 (en) 2004-08-20 2006-03-02 Tishcon Corp Synergistic conjugated linoleic acid (cla) and carnitine combination
US20060051462A1 (en) * 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
US7288263B2 (en) * 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
ZA200703087B (en) * 2004-09-17 2009-04-29 Inst Of Medicinal Biotechno Methods and compositions for the treatment of hyperlipidemia
US20060062755A1 (en) 2004-09-21 2006-03-23 Woodward John R Method of cancer screening; method of cancer treatment; and method of diabetes treatment
JP5093998B2 (ja) 2004-09-22 2012-12-12 大塚製薬株式会社 色素沈着予防又は改善剤
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
WO2006035417A2 (en) 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
WO2006044738A2 (en) 2004-10-18 2006-04-27 Maroon Biotech Corporation Methods and compositions for treatment of free radical injury
WO2006050155A2 (en) 2004-10-29 2006-05-11 Biomune, Inc. Cancer therapeutic compositions
WO2006048159A1 (en) * 2004-11-02 2006-05-11 Dsm Ip Assets B.V. Additive for uv-sunscreen preparations
US8349359B2 (en) 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
GB0424891D0 (en) 2004-11-11 2004-12-15 Boots Co Plc Topical compositions
CA2587677C (en) * 2004-11-16 2013-05-28 Bioavailability, Inc. High concentration self-microemulsifying coenzyme q10 preparations for nutritional use
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20060127384A1 (en) 2004-12-09 2006-06-15 Sergio Capaccioli Coenzyme Q10 as antiapoptotic agent
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
WO2006063733A1 (en) * 2004-12-14 2006-06-22 F.Hoffmann-La Roche Ag Cd99 as target/marker for insulin resistance
WO2006063402A1 (en) 2004-12-16 2006-06-22 Melvin Mackenzie Stewart Therapeutic compositions based on extracts of plants from the genus plumeria (frangipani)
NO20045674D0 (no) * 2004-12-28 2004-12-28 Uni I Oslo Thin films prepared with gas phase deposition technique
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
US20060188492A1 (en) 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
DE102005007980A1 (de) 2005-02-22 2006-02-23 Clariant Gmbh Kosmetische, pharmazeutische oder dermatologische Zubereitungen enthaltend Copolymerwachse
WO2006103750A1 (ja) 2005-03-29 2006-10-05 Nippon Meat Packers, Inc. 肥満改善用組成物、機能性食品及び医薬用組成物
US20060251690A1 (en) 2005-04-01 2006-11-09 Zymes, Llc Skin enrichment using CoQ10 as the delivery system
CN1853507A (zh) * 2005-04-28 2006-11-01 尚宝虎 一种没有副作用的可用于饮料和固体口服制剂或食品添加的减肥新组方
JP2007001922A (ja) 2005-06-23 2007-01-11 Asahi Kasei Pharma Kk 透析患者における腎疾患改善剤、又は機能性食品
EP1909763A2 (en) 2005-07-28 2008-04-16 Isp Investments Inc. Benzoquinones of enhanced bioavailability
JPWO2007013556A1 (ja) * 2005-07-28 2009-02-12 株式会社カネカ 癌予防用組成物
US20070053985A1 (en) * 2005-08-24 2007-03-08 Kaneka Corporation Coenzyme Q10-containing fine particle with excellent dispersibility
CN1928556A (zh) * 2005-09-05 2007-03-14 中国医学科学院基础医学研究所 中国人2型糖尿病血清标志物的检测试剂盒
US20070071779A1 (en) * 2005-09-26 2007-03-29 Leggit Ingenuity, Llc Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof
EP1876448A1 (en) * 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones.
US20070092469A1 (en) 2005-10-26 2007-04-26 Eric Jacobs Topically applied Glucosamine Sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while PhosphatidylCholine is required to replace its deficiency caused by topical Dimethylaminoethanol (DMAE)
US8506956B2 (en) * 2005-10-31 2013-08-13 Kaneka Corporation Method for stabilizing reduced coenzyme Q10
US9265792B2 (en) 2005-11-16 2016-02-23 Patricia A. Riley Integument cell regeneration formulation
CA2631236C (en) 2005-12-01 2019-10-29 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20070248590A1 (en) 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
JP2007176804A (ja) * 2005-12-27 2007-07-12 Ｚｍｃ−Ｋｏｕｇｅｎ株式会社 痩身作用を有する医薬又は健康食品
US20070172436A1 (en) 2006-01-23 2007-07-26 Jerry Zhang Nonaqueous ascorbic acid compositions and methods for preparing same
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
US20070184041A1 (en) 2006-02-09 2007-08-09 Burja Adam M Methods and compositions related to production of coenzyme q10
CA2642342A1 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers
US20070203091A1 (en) 2006-02-28 2007-08-30 Eliezer Rapaport Methods and therapeutic compositions for improving liver, blood flow and skeletal muscle functions in advanced diseases and aging
JP5678359B2 (ja) 2006-03-10 2015-03-04 ラボスイス アーゲー 物質を可溶化、分散、および安定化させる方法とその方法により製造される生成物とその使用
US7335384B2 (en) 2006-03-17 2008-02-26 4K Nutripharma International Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
US8030013B2 (en) 2006-04-14 2011-10-04 Mount Sinai School Of Medicine Methods and compositions for the diagnosis for early hepatocellular carcinoma
TW200808344A (en) 2006-04-28 2008-02-16 Kaneka Corp Stabilization method of reduced coenzyme Q10
TW200810776A (en) 2006-04-28 2008-03-01 Kaneka Corp Purification method of reduced coenzyme Q10
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
ES2836184T3 (es) 2006-05-02 2021-06-24 Univ Miami Formulaciones tópicas de co-enzima Q10 y tratamiento de heridas
US20090191575A1 (en) 2006-06-05 2009-07-30 Makoto Watanabe Tumor marker and method for determination of the occurrence of cancerous disease
US20080020022A1 (en) * 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
US20080014187A1 (en) * 2006-07-15 2008-01-17 Bryant Villeponteau Compositions and Methods for Treating Hypertension and Inflammation
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
JPWO2008069276A1 (ja) 2006-12-06 2010-03-25 株式会社カネカ 癌治療剤および発癌抑制剤
CN101015524B (zh) * 2007-02-15 2011-09-14 沈阳药科大学 辅酶q10口服乳剂及其制备方法
AU2008228764B2 (en) * 2007-03-22 2014-05-08 Berg Llc Topical formulations having enhanced bioavailability
US20090143279A1 (en) * 2007-06-15 2009-06-04 Vamsi Krishna Mootha Methods and compositions for treating metabolic disorders
US20090005398A1 (en) 2007-06-27 2009-01-01 Mohammed Dar Methods For The Treatment of Central Nervous System Tumors
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
KR100849537B1 (ko) 2007-07-04 2008-07-31 유효경 코엔자임 큐텐의 나노에멀젼 조성물
JP5701601B2 (ja) 2007-07-17 2015-04-15 メタボロン インコーポレイテッド 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法
CN101091890A (zh) 2007-07-26 2007-12-26 沈阳药科大学 一种复合型乳化剂及用其制备的乳剂及其制备方法
WO2009026163A1 (en) 2007-08-17 2009-02-26 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
RU2345367C1 (ru) 2007-08-22 2009-01-27 Государственное образовательное учреждение высшего профессионального образования Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО НГМУ Росздрава) Способ прогнозирования тяжести течения и эффективности лечения лимфом
JP2009050168A (ja) 2007-08-23 2009-03-12 Tsujido Kagaku Kk 食品組成物
EP2197917A1 (en) 2007-09-28 2010-06-23 Universitätsspital Basel Immunoliposomes for treatment of cancer
JP2009096757A (ja) * 2007-10-17 2009-05-07 Tsujido Kagaku Kk 脂肪代謝抑制剤
WO2009073843A1 (en) * 2007-12-06 2009-06-11 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
CN102083424B (zh) 2008-04-11 2013-08-28 细胞研究有限公司 诱导癌细胞凋亡的方法和应用
JP5945096B2 (ja) 2008-07-04 2016-07-05 小野薬品工業株式会社 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
JP5705127B2 (ja) 2008-12-03 2015-04-22 アモーサイト インコーポレイテッド 梗塞領域灌流改善組成物および血管損傷修復の方法
DE102008060773A1 (de) 2008-12-05 2010-06-10 Sartorius Stedim Biotech Gmbh Verschluss für einen Behälter
US8247435B2 (en) 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
AU2010247750B2 (en) 2009-05-11 2016-09-22 Berg Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
EA201270325A1 (ru) * 2009-08-25 2012-11-30 Ситотех Лэбс, Ллс Способы лечения саркомы с использованием эпиметаболической сдвигающей добавки (кофермента q10)
US8506954B2 (en) 2009-12-01 2013-08-13 The Board Of Trustees Of The Leland Stanford Junior University Tumor vaccination in combination with hematopoietic cell transplantation for cancer therapy
KR102008658B1 (ko) 2010-03-12 2019-08-08 베르그 엘엘씨 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법
KR20180123176A (ko) 2010-07-19 2018-11-14 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
US9125835B2 (en) 2010-11-12 2015-09-08 Rutgers, The State University Of New Jersey Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases
EP2691112B1 (en) 2011-03-31 2018-05-23 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
KR101933732B1 (ko) 2011-04-04 2018-12-28 버그 엘엘씨 중추 신경 시스템 종양들의 치료 방법
AU2013260271B2 (en) 2012-04-03 2017-06-01 Quizcamp-Fabrico E Comercio De Produtos Alimentares, S.A. Modular integrated system for seed germination, cultivation, planting, fertilizing and maintenance of plants
IN2014DN10734A (enExample) 2012-06-01 2015-09-04 Berg Llc
SG11201508272YA (en) 2013-04-08 2015-11-27 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
HUE050060T2 (hu) 2013-09-04 2020-11-30 Berg Llc Eljárások rák kezelésére koenzim Q10 folyamatos infúziójával
JP6398212B2 (ja) 2014-02-12 2018-10-03 株式会社Ihi 軸受構造、および、過給機
AU2015327887A1 (en) 2014-10-03 2017-04-13 The Board Of Trustees Of The Leland Stanford Junior University Use of annexin V as a method to block tumor induced immunosuppression of the innate immune response
WO2016062722A1 (en) 2014-10-24 2016-04-28 Astrazeneca Ab Combination
WO2016094639A1 (en) 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
WO2018018018A1 (en) 2016-07-21 2018-01-25 Berg Llc Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
US10373477B1 (en) 2016-09-28 2019-08-06 Gojo Industries, Inc. Hygiene compliance modules for dispensers, dispensers and compliance monitoring systems
JP6895250B2 (ja) 2016-12-28 2021-06-30 日東電工株式会社 表面保護フィルム
CN116236688A (zh) 2018-07-03 2023-06-09 埃德温·阊 使用交变电场提高细胞膜通透性
US20200138744A1 (en) 2018-10-15 2020-05-07 Berg Llc Methods of treating pancreatic cancer using coenzyme q10
WO2021102356A1 (en) 2019-11-20 2021-05-27 Berg Llc Combination therapy of a coenzyme q10 compound and radiation therapy for treatment of glioma

Also Published As

Publication number Publication date
IL216297A0 (en) 2012-01-31
CN104825429A (zh) 2015-08-12
KR20120060945A (ko) 2012-06-12
MX349796B (es) 2017-08-11
JP2017214413A (ja) 2017-12-07
EP2430194A4 (en) 2013-09-04
MX2011011940A (es) 2012-06-25
KR101829201B1 (ko) 2018-02-19
KR20180018833A (ko) 2018-02-21
US20110123987A1 (en) 2011-05-26
WO2010132507A3 (en) 2011-03-31
AU2016222515A1 (en) 2016-09-22
CA2763325A1 (en) 2010-11-18
AU2010247750B2 (en) 2016-09-22
US20110123986A1 (en) 2011-05-26
BRPI1010648A2 (pt) 2016-03-15
CN102482713B (zh) 2017-06-30
CN102481269B (zh) 2015-10-07
JP2018048125A (ja) 2018-03-29
IL216295A0 (en) 2012-01-31
CA2761717A1 (en) 2010-11-18
WO2010132507A2 (en) 2010-11-18
AU2010247755A1 (en) 2011-12-15
JP6081195B2 (ja) 2017-02-15
JP2018021064A (ja) 2018-02-08
CN102481269A (zh) 2012-05-30
US20210332439A1 (en) 2021-10-28
JP2017018134A (ja) 2017-01-26
SG10201402293SA (en) 2014-08-28
MX351083B (es) 2017-09-29
US20160145693A1 (en) 2016-05-26
CA2763336A1 (en) 2010-11-18
CN102482713A (zh) 2012-05-30
AU2010247800A1 (en) 2011-12-15
US20170137879A1 (en) 2017-05-18
EA023913B1 (ru) 2016-07-29
AU2016222422A1 (en) 2016-09-22
CA2763336C (en) 2018-10-30
US20210002725A1 (en) 2021-01-07
CN102483419A (zh) 2012-05-30
BRPI1010908A2 (pt) 2016-03-15
AU2010247734B2 (en) 2016-04-14
WO2010132440A3 (en) 2011-04-07
US20110020312A1 (en) 2011-01-27
KR20120034647A (ko) 2012-04-12
CN102481270A (zh) 2012-05-30
US20110027247A1 (en) 2011-02-03
US20220081720A1 (en) 2022-03-17
JP2016023189A (ja) 2016-02-08
US20180334721A1 (en) 2018-11-22
IL216298A0 (en) 2012-01-31
SG10201402287TA (en) 2014-07-30
AU2010247755B2 (en) 2016-09-15
EP2429511B1 (en) 2019-02-20
AU2010247761A1 (en) 2011-12-15
US10351915B2 (en) 2019-07-16
MX2011011949A (es) 2012-02-13
EA201101523A1 (ru) 2012-10-30
EP2429511A4 (en) 2013-08-28
WO2010132502A2 (en) 2010-11-18
EP2430455A2 (en) 2012-03-21
JP6254979B2 (ja) 2017-12-27
IL216299A0 (en) 2012-01-31
US20200157630A1 (en) 2020-05-21
MX2011011947A (es) 2012-01-30
BRPI1011025A2 (pt) 2016-03-29
CN105287449A (zh) 2016-02-03
KR20140014390A (ko) 2014-02-06
WO2010132486A3 (en) 2011-03-03
US10519504B2 (en) 2019-12-31
US9896731B2 (en) 2018-02-20
WO2010132502A3 (en) 2011-04-21
JP2012526829A (ja) 2012-11-01
SG10201402288RA (en) 2014-07-30
JP5903734B2 (ja) 2016-04-13
EA034552B1 (ru) 2020-02-19
JP6169846B2 (ja) 2017-07-26
SG175996A1 (en) 2011-12-29
SG175994A1 (en) 2011-12-29
US20110110914A1 (en) 2011-05-12
EP2429512A2 (en) 2012-03-21
MX345044B (es) 2017-01-16
AU2010247750A1 (en) 2011-12-15
JP2016023190A (ja) 2016-02-08
EP2429513A2 (en) 2012-03-21
AU2016269471A1 (en) 2016-12-22
WO2010132440A2 (en) 2010-11-18
EP2429512A4 (en) 2013-07-31
AU2016204621A1 (en) 2016-07-21
EP2429513A4 (en) 2013-08-14
CN102483419B (zh) 2017-12-15
JP5903735B2 (ja) 2016-04-13
SG175992A1 (en) 2011-12-29
KR20180056816A (ko) 2018-05-29
WO2010132479A2 (en) 2010-11-18
JP2012526824A (ja) 2012-11-01
IL216296B (en) 2020-06-30
KR20120034649A (ko) 2012-04-12
CN102481271A (zh) 2012-05-30
EA201101521A1 (ru) 2012-09-28
BRPI1011025A8 (pt) 2016-07-19
JP2015199746A (ja) 2015-11-12
MX2011011942A (es) 2011-12-06
EA201101519A1 (ru) 2012-10-30
KR101860294B1 (ko) 2018-07-02
SG175993A1 (en) 2011-12-29
KR20120088555A (ko) 2012-08-08
SG10201402291QA (en) 2014-07-30
EP2429511A2 (en) 2012-03-21
JP2012526555A (ja) 2012-11-01
EP2430194A2 (en) 2012-03-21
WO2010132479A3 (en) 2011-03-31
EA201101520A1 (ru) 2012-09-28
JP2012526828A (ja) 2012-11-01
EP2430455A4 (en) 2013-09-04
SG10201402289VA (en) 2014-07-30
US12209285B2 (en) 2025-01-28
US20180355435A1 (en) 2018-12-13
AU2010247734A1 (en) 2011-12-15
BRPI1010827A2 (pt) 2019-09-24
JP2017074038A (ja) 2017-04-20
US20150023940A1 (en) 2015-01-22
EA201101522A1 (ru) 2012-09-28
US11028446B2 (en) 2021-06-08
BRPI1010576A2 (pt) 2016-03-15
JP2012526554A (ja) 2012-11-01
MX2011011958A (es) 2012-02-13
US20190010554A1 (en) 2019-01-10
US9205064B2 (en) 2015-12-08
SG175991A1 (en) 2011-12-29
CA2762213A1 (en) 2010-11-18
CA2763347A1 (en) 2010-11-18
IL216296A0 (en) 2012-01-31
WO2010132486A2 (en) 2010-11-18
CA2763347C (en) 2021-11-23

Similar Documents

Publication Publication Date Title
MX357528B (es) Metodos para el tratamiento de trastornos metabolicos usando intercambiadores epimetabolicos, moleculas intracelulares multidimensionales o influencias ambientales.
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
PT2514436T (pt) Il-22 para utilização no tratamento de distúrbios microbianos
CO6791606A2 (es) Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
EP2844289A4 (en) Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
ECSP10010007A (es) Tratamiento con ligandos alpha-7-selectivos
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX373306B (es) Composiciones y métodos para modular la expresión de la apolipoproteína c-iii.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20140096A (es) Pirimidinas anilladas sustituidas y uso de las mismas
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
BRPI0922384A2 (pt) "manipulador de suprimento para equipamento".
DOP2013000007A (es) Pirimidinadas y triazinas condensadas y su uso
HUE045629T2 (hu) Készítmények, alkalmazások és eljárások anyagcsere rendellenességek és betegségek kezelésére
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0919388A2 (pt) ácido succínico e método para produzir o mesmo.
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
WO2011153460A3 (en) Therapeutic amoeba and uses thereof
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
ATE531715T1 (de) 1,3-dihydro-2h-pyrroloä3.2-büpyridin-2-onderiva e,deren herstellung und deren therapeutische verwendungen
CL2009000257A1 (es) Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico.
DK2155179T3 (da) Axomadol til smertebehandling arthrose
UY30570A1 (es) Derivaods de feniloxianilina